Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Overview

Explore Amylyx Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

AMLX●NASDAQ
HealthcareBiotechnology
$33.64
$2.02(6.39%)
U.S. Market opens in 7h 53m

Amylyx Pharmaceuticals, Inc. (AMLX)

Meyka AI Score

Z

Key Financials

Market Cap3.7B
P/E Ratio-22.70
EPS (TTM)$-1.50
ROE-0.53%
Fundamental Analysis

AI Price Forecasts

1 Month$40.13
3 Months$30.00
1 Year Target$7.36

AMLX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Amylyx Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of AMLX on the NASDAQ shows an RSI of 59.43, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $7.36 for the NASDAQ listing.

Key metrics behind Amylyx Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -22.70 and a market capitalization of 3.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of AMLX on the NASDAQ.

Price Performance (NASDAQ: AMLX)

1-Day Change
6.39%
5-Day Change
0.42%
1-Month Change
55.52%
3-Month Change
130.57%
6-Month Change
140.46%
Year-to-Date (YTD) Change
178.48%
1-Year Change
183.88%
3-Year Change
71.55%
5-Year Change
86.16%
All-Time (Max) Change
86.16%

Contact Information

https://amylyx.com
617 682 0917
55 Cambridge Parkway, Cambridge, MA, 02142

Company Facts

1,360 Employees
IPO DateJan 7, 2022
CountryUS
Actively Trading

Frequently Asked Questions